A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera� in patients with CD20-positive B-cell non-Hodgkin lymphoma
Xiaohong Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuhuan Gao(Hebei Medical University), Liangzhi Xie(Sinocelltech Group (China)), Lin Gui(Chinese Academy of Medical Sciences & Peking Union Medical College), Hang Su(307th Hospital of Chinese People’s Liberation Army), Wenlin Gai(Sinocelltech Group (China)), Wei Li(Jilin University), Mingzhi Zhang(Chinese Academy of Sciences), Xiaonan Hong(Fudan University Shanghai Cancer Center), Qingyuan Zhang(Third Affiliated Hospital of Harbin Medical University), Huaqing Wang(Tianjin People's Hospital), Yun Tang(Sichuan University), Hanyun Ren(Peking University), Miao-Wang Hao(Tang Du Hospital), Jie Jin(Beijing Institute of Technology), Jianmin Luo(Hebei Medical University), Xiaoyan Ke
Cited by 5
Related Papers
Aspect-based sentiment analysis via affective knowledge enhanced graph convolutional networks
|Knowledge-Based Systems|2021|518
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250